Equities research analysts expect that Alkermes PLC (NASDAQ:ALKS) will post $239.12 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Alkermes PLC’s earnings. The lowest sales estimate is $237.50 million and the highest is $241.10 million. Alkermes PLC reported sales of $213.51 million in the same quarter last year, which indicates a positive year over year growth rate of 12%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, February 21st.
According to Zacks, analysts expect that Alkermes PLC will report full year sales of $239.12 million for the current financial year, with estimates ranging from $852.40 million to $900.00 million. For the next fiscal year, analysts expect that the business will report sales of $988.96 million per share, with estimates ranging from $886.40 million to $1.07 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Alkermes PLC.
Alkermes PLC (NASDAQ:ALKS) last issued its earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The firm had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $231.29 million. During the same quarter last year, the company posted ($0.09) earnings per share. Alkermes PLC’s revenue was up 20.6% on a year-over-year basis.
Shares of Alkermes PLC (NASDAQ:ALKS) traded up $0.39 during midday trading on Friday, reaching $48.08. 946,800 shares of the company’s stock were exchanged, compared to its average volume of 833,495. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes PLC has a 1 year low of $46.42 and a 1 year high of $63.40.
In other Alkermes PLC news, SVP James M. Frates sold 20,932 shares of Alkermes PLC stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $47.58, for a total value of $995,944.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of Alkermes PLC stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $50.77, for a total transaction of $76,155.00. Following the completion of the transaction, the director now owns 9,500 shares in the company, valued at approximately $482,315. The disclosure for this sale can be found here. In the last 90 days, insiders sold 102,498 shares of company stock worth $5,018,010. 5.34% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of ALKS. Toronto Dominion Bank boosted its stake in Alkermes PLC by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares during the period. Quantbot Technologies LP acquired a new position in Alkermes PLC in the 3rd quarter worth approximately $126,000. Virtu Financial LLC acquired a new position in Alkermes PLC in the 3rd quarter worth approximately $201,000. Dynamic Technology Lab Private Ltd acquired a new position in Alkermes PLC in the 3rd quarter worth approximately $214,000. Finally, Trexquant Investment LP acquired a new position in Alkermes PLC in the 3rd quarter worth approximately $218,000. 98.11% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Alkermes PLC (ALKS) Will Announce Quarterly Sales of $239.12 Million” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/16/zacks-analysts-anticipate-alkermes-plc-alks-will-announce-quarterly-sales-of-239-12-million.html.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.